Hormonal
SGLT2 inhibitors provide significant cardiovascular and renal protection in patients with type 2 diabetes, heart failure, and chronic kidney disease, independent of glycemic control.
If you have Type 2 Diabetes along with heart failure or kidney disease, SGLT2 inhibitors (like Jardiance, Farxiga, or Trulicity's cousin) are now a standard, first-line treatment. They protect your heart and kidneys regardless of your blood sugar numbers. Discuss starting one with your doctor immediately, as guidelines strongly recommend it for this specific patient profile.
These drugs have revolutionized the management of patients with diabetic CKD with high risk for cardiovascular events, independent of glycemic control.
Why this rating
Supported by multiple large-scale RCTs (EMPA-REG, CANVAS, DAPA-HF, CREDENCE, etc.) with consistent positive outcomes.
Source
Cardiorenal syndrome and diabetes: an evil pairing
Ana Belén Fernández et al. · Frontiers in Cardiovascular Medicine · 2023
DOI 10.3389/fcvm.2023.1185707
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →